8-K: C4 Therapeutics Announces 2025 Milestones and Provides Portfolio Update

C4 Therapeutics anticipates key data readouts and clinical trial advancements across its degrader medicine portfolio in 2025, with cash runway extending into 2027.

Summary

• C4 Therapeutics (C4T) announced its anticipated milestones for 2025, focusing on advancing its clinical-stage programs and leveraging its TORPEDO platform.
• The company expects to initiate the next phase of clinical development for cemsidomide in multiple myeloma (MM) and peripheral T-cell lymphoma (PTCL) in early 2026.
• Phase 1 dose escalation data for cemsidomide in MM and NHL is expected in the second half of 2025, with expansion cohorts opening in PTCL.
• For CFT1946, C4T aims to complete monotherapy Phase 1 dose escalation in BRAF V600 mutant solid tumors in the first half of 2025 and present Phase 1 data in the second half of 2025.
• Data from the CFT8919 Phase 1 dose escalation study in Greater China will inform future development plans outside of China.
• C4T expects its cash, cash equivalents, and marketable securities as of December 31, 2024, will fund its operating plan into 2027.
• C4T presented at the J.P. Morgan Healthcare Conference on January 15, 2025.
• Cemsidomide demonstrated a 38% ORR across all NHL subtypes and doses studied, and a 44% ORR with a 25% complete metabolic response rate in PTCL.
• CFT1946 has demonstrated initial signs of anti-tumor activity across all dose levels and is well tolerated.
• CFT1946 has the ability to cross the blood-brain barrier, with Kpu,u values in the range of 0.34 to 0.88.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for C4 Therapeutics, highlighting key milestones, clinical trial progress, and a strong cash position. The company's focus on targeted protein degradation and its TORPEDO platform suggests potential for future growth and innovation.

Positives

• C4 Therapeutics has a strong cash position, expected to fund operations into 2027.
• Cemsidomide shows promising clinical data, with potential as a backbone therapy in multiple myeloma and non-Hodgkins lymphoma.
• CFT1946 demonstrates early signs of anti-tumor activity and is well-tolerated in Phase 1 trials.
• CFT8919 is progressing through Phase 1 dose escalation in Greater China.
• The TORPEDO platform continues to generate development candidates and attract collaborations.
• CFT1946 has the ability to cross the blood-brain barrier, with Kpu,u values in the range of 0.34 to 0.88.

Risks

• The information provided is unaudited and preliminary, and the audit of the company's consolidated financial statements for the year ended December 31, 2024, could result in changes to the information.
• Forward-looking statements are subject to risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, and funding availability.

Future Outlook

C4 Therapeutics anticipates a pivotal year in 2025 with key data readouts and clinical trial advancements across its degrader medicine portfolio, aiming to advance programs and bring degrader medicines to patients.

Management Comments

• Stellar execution in 2024 has set up 2025 to be a pivotal year for the company as we work to generate important data that will position us to advance programs and bring degrader medicines to patients searching for new therapeutic options, said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
• We are excited about the degrader rationale for these programs, which we believe have the potential to deliver value for patients, caregivers, physicians and shareholders.

Industry Context

C4 Therapeutics is operating in the competitive field of targeted protein degradation, aiming to develop novel therapies for oncology and other diseases. The company's focus on orally bioavailable degraders and its TORPEDO platform positions it to potentially address limitations of existing therapies and drug resistance mechanisms.

Comparison to Industry Standards

• Cemsidomide is being developed as a potentially best-in-class IKZF1/3 degrader, with the goal of improved potency and selectivity compared to existing and development-stage IKZF1/3 degraders.
• CFT1946 is the only degrader of BRAF V600 mutant solid tumors in clinical trials, differentiating it from BRAF inhibitors that have limitations due to resistance mechanisms and toxicities.
• CFT8919 is designed to be a potent and selective EGFR L858R degrader, potentially overcoming resistance mutations and tolerability issues associated with current EGFR inhibitors.

Stakeholder Impact

• Shareholders: The announcement provides updates on the company's progress and future plans, which may influence investor confidence.
• Patients: The development of new degrader medicines has the potential to improve treatment options and outcomes for patients with cancer and other diseases.
• Employees: The company's continued progress and strong financial position may provide job security and opportunities for growth.
• Collaboration partners: The advancement of internal and collaboration programs to key milestones may strengthen partnerships and lead to further collaborations.

Next Steps

• Initiate the next phase of clinical development for cemsidomide in multiple myeloma and peripheral T-cell lymphoma in early 2026.
• Complete Phase 1 dose escalation and present data for cemsidomide in MM and NHL in the second half of 2025.
• Open expansion cohort(s) of the current Phase 1/2 trial in patients with peripheral T-cell lymphoma (PTCL) in the second half of 2025.
• Complete monotherapy Phase 1 dose escalation in BRAF V600 mutant solid tumors for CFT1946 in the first half of 2025.
• Generate data from the Phase 1 cohorts exploring monotherapy CFT1946 in melanoma, CFT1946 in combination with cetuximab in CRC and CFT1946 in combination with trametinib in melanoma.
• Evaluate data from the Phase 1 dose escalation study in Greater China for CFT8919 to determine the next phase of development.
• Present and publish preclinical work from its internal pipeline and TORPEDO platform.
• Advance internal and collaboration programs to key milestones.

Key Dates